Overview

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
Phase:
Phase 1
Details
Lead Sponsor:
Elan Pharmaceuticals